The purpose of this study is to examine the safety of ABX-EGF administered as monotherapy in subjects with metastatic colorectal cancer who were previously randomized to best supportive care (BSC) in protocol 20020408 and subsequently determined to have progressive disease.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Incidence of Adverse events
Changes in Lab values
Incidence of HAHA formation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.